horiz (2)horiz (2)horiz (2)horiz (2)
  • Solutions
    • PepsinCheck
    • Reflux Band
    • Dx-pH System
    • Stretta
    • Secca
  • Clinicians
  • Patients
  • Blog
  • Events
  • Clinical Library
  • Login
✕
“In Patients with GERD Globus is Associated with Abnormal Oropharyngeal Acid Exposure”
May 14, 2019
Reflux: Is the Treatment More Risky than the Disease?
September 27, 2019

Background:

A 56-year old woman presented with disabling reflux dyspeptic symptoms with episodes of nausea, vomiting, sore throat, retrosternal pain, heartburn, and early morning taste of blood in the saliva. Patient gave a history of food and acid regurgitation with diurnal as well as nocturnal symptoms affecting quality of life and sleep. Her heartburn scores were 4/5 pre- and post-prandial and 5/5 nocturnal (with 5 being the worst). LPR symptoms included sore throat with some vocal irritation. She had a few hospital admissions with above symptoms and chest pain, where she had multiple investigations including scans, oesophageal pH studies, manometry studies, barium swallow and endoscopy studies together with ENT assessments. Endoscopy revealed lax junction, with erosive oesophagitis, visibly refluxing gastric contents and without hiatus hernia as on HRM. DeMeester score was within normal range alongside symptom index (SI) of 69% on pH studies. Oesophageal biopsies showed inflammatory changes without eosinophilic oesophagitis. She was treated with various PPI’s, antacids, analgesia including Zomorph with minimal effect. Her quality of life was substantially affected, including significant depression.

Patient’s Testimony:

“Since the middle of 2012 I had experienced severe prolonged bouts of acid reflux that controlled my life. The long-term effects caused considerable pain and inflammation of the oesophagus and stomach. I was even hospitalised on one occasion because I was unable to keep any food down for a week due to the inflammation. I also experienced waking up with a metallic taste in my mouth. I was on high doses of anti-reflux and pain medications, including morphine and co-codamol. The health issues I was experiencing interfered with my work, social and home life, I even needed to take considerable time off work due to the ongoing pain I suffered at times. My husband and I were finding no grace with the mainstream medical profession as I was outside the box. I came across Prof. Viswanath in Nuffield Hospital, Stockton-on-Tees, who spoke of an endoscopic radio-frequency (Stretta) therapy available for reflux problems. Shortly after visiting Prof. Vis, I went ahead with it and I have not looked back. I found the procedure non-invasive and I had a relatively quick recovery, returning to work after one week. There was some pain and discomfort at first. I was on a liquid diet for six weeks and then soft food for a while, but every step was worth it. It has been four months since the Stretta procedure, I do occasionally use an anti-reflux liquid but otherwise I am off all other forms of anti-reflux medication and pain killers. I do consider what I eat and drink but my quality of life has improved 99% and I would recommend anyone experiencing what I suffered to consider the Stretta procedure. I found Prof. Vis and all the staff at Nuffield very amicable and helpful. The hospital was very comfortable which also made me feel at ease and not so nervous. I am now looking forward to my relatively reflux – and pain – free future. Thank you Prof. Viswanath for listening and assisting me with this health issue that has improved my life and future.”

Treatment and follow up:

Patient was seen and counseled, underwent endoscopic assessment to find lax gastrooesophageal (GO) junction (Grade 2 Hill’s endoscopic grading), without hiatus hernia along with erosive oesophagitis. Following on, she was initially counseled with pictures, videos, and leaflets about Stretta Therapy. She underwent Stretta Therapy as a day case under general anesthesia (patient wishes), although in our practice 80% are done under sedation. At endoscopy, GO junction was located at 37.5cm. At 6 levels, RF energy was delivered, so as to administer 56 thermal lesions at the lower oesophageal sphincter (LES) zone. 6 months following Stretta therapy, she is off pain killers including morphine and PPI’s, and claims all her reflux symptoms have improved considerably. This has led to a large improvement to her quality of life.

Discussion

Gastrooesophageal reflux disease (GORD) with classical symptoms alongside good symptom association probability (SAP) and symptom sensitivity (SI) usually responds well to medical and/or interventional endoscopic or laparoscopic therapy. GERD/GORD patients who fail to respond to medical treatment and those who do not wish to remain on long-term medication are offered alternate therapy, including surgery. However, patients such as this case, in which the presentation is convoluted with some classical and LPR symptoms along with severe nausea, vomiting and/or chest pains, are difficult to adjudicate for surgery. Surgery is invasive and associated morbidities such as dysphagia & gas bloat could affect patients adversely. This particular patient was assessed by gastroenterologists, ENT surgeons and Upper GI surgeons, who advised against surgery (with which I also agreed). She had a normal DeMeester score, underscoring weakly acidic reflux with a positive symptom index; however no impedance test was done in the referring hospital. Patient was extremely keen to be considered for an intervention, including surgery, if recommended. A measure of all reports and assessments was taken prior to recommending Stretta. Any such patients require all diagnostic assessments with thorough counseling. Bearing on her wishes, consent, counseling and suitability, endoscopic radiofrequency (RF) anti-reflux Stretta Therapy was carried out as a day case with an excellent outcome. A thorough assessment with unconcealed and meticulous counseling is essential prior to offering Stretta, especially in GORD patients presenting with a combination of classical reflux with LPR and some nonconforming symptoms.

Download a copy of this Case Study

Professor Viswanath YKS is a senior Consultant Surgeon specializing in upper GI and advanced laparoscopic & endoscopic surgery at James Cook University Hospital. He holds a visiting chair at Teesside University and is the programme director for MCh postgraduate surgical specialities. With the Universities of Teeside and Durham, Prof Viswanath has supervised PhD, MSc MCh and MPhil students. A recognised national trainer for advanced laparoscopic surgery, he contributes via the ALSGBI council by running live courses. These include TAPP hernia and Stretta training courses for which he established the National ‘Endo RF Anti-reflux’ Therapy (Stretta) Centre in the UK. Prof Viswanath’s research interests are mainly focused in Upper Gastro-intestinal (Oesophago-Gastric) cancer including Barrett’s metaplasia, with particular interests in ‘Cancer Immunology and molecular biology’ in OG cancer. He remains active in research, having presented more than 200 abstracts in national & international meetings, and publishing both clinical and scientific papers.

 

 

Share

Related posts

March 3, 2022

Study finds significant correlation between LPR and Allergic Rhinitis


Read more
January 18, 2021

16 Million New Patients Covered for Stretta Therapy


Read more
November 19, 2020

Minimally Invasive Stretta Antireflux Procedure Accessible to Millions more Patients


Read more
Stopped Pain Killers, Morphine Supplements, Antacids with 99% Improvement in Quality of Life After Stretta Therapy
CONTACT

US: +800.352.1512
Int'l: +1 858.673.3700
Fax: 858.673.3783 contact@restech.com

Contact

Distributor Login
Clinician Login
Representative Login

How we Help

Solutions
PepsinCheck
Reflux Band
Restech
Stretta
Secca

About Us

Company
Contact Us
Job Opportunities
International Distributors
Compliance
Privacy Policy
Terms of Use

Follow Us

Respiratory Technology Corporation 11011 Brooklet Dr, Ste 300 Houston TX 77099 | © 2019 Restech. All Rights Reserved.
    FIND A DOCTOR
      Bree Gorman, VP Marketing

      Bree has been an integral part of Restech from the very beginning. She holds a Masters in Public Health from George Washington University, a BFA from The University of Kansas in Visual Communications, and is a National Board Certified Health & Wellness Coach. Her command of marketing, public health/health delivery systems, and human health behavior change gives her a unique perspective in developing effective marketing strategies for the company.  

      Physicians: Fill out the form below to complete your request to be added to the “Find-A-Doctor” map on restech.com

       


      Thomas Ball, PhD, VP Clinical Affairs

      Thomas previously worked as a polysomnographic technologist in the Virginia Mason system, before  moving into sales with Restech in 2007. After spending 9 years working with distributors across Europe, he was moved into an organizational role at the head office in Houston. In this capacity he works closely with sales and marketing to provide clinical support, manages clinical studies, and provides clinical perspectives on business development. In his spare time Thomas plays rugby for Houston Athletic Rugby Club.

      Jeff Klindworth, VP Business Development

      Jeff has over 30 years of experience in the medical device industry and previously worked in sales at companies such as Encision Inc., Interventional Therapies, LLC, Boston Scientific, and United States Surgical Corporation. He has been working as the VP of Sales for Mederi Therapeutics since 2009 and now brings his extensive expertise to Restech.  Jeff was part of the team that bridged the Mederi asset sale to Restech.  His clinical knowledge of the Stretta and Secca technologies is invaluable.  Jeff has three decades of physician relations experience that he brings to Restech as part of the leadership team.

      Ray Bengermino, VP Sales

      Ray joined Restech in May 2018 as the Vice President for Sales. He has been in the medical device, and specifically in the GERD space for more than 18 years. Starting in sales at Sandhill Scientific pH diagnostics, he moved on to Curon Medical when Stretta and Secca were first introduced to the market. He then worked for Given Imaging when Curon closed operations.  When Stretta was relaunced he joined Mederi as VP of Sales.  Ray was instrumental in keeping Stretta alive and the customer based informed when Mederi ceased operation and assets were purchased by Restech.  He is part of the leadership team directing all product sales for Restech. Ray graduated from Old Dominion University in Norfolk with a BS in Marketing and Business Administration.

      Mark Clark, CPA, CFO

      Mark is a seasoned professional and Certified Public Accountant in Texas who brings a unique blend of creative vision and financial expertise to any leadership team. He worked as a Senior Executive for 15 years on a leadership team which grew a private equity backed cash logistics company performing at negative EBITDA on $100 million revenue into an international industry leader with superior profitability on revenue exceeding $1.5 billion. In addition, he spent 10 years as a Senior Manager at Price Waterhouse delivering results-oriented merger & acquisition, audit and strategic consulting services to middle market clientele including over 40 manufacturing, distribution, service, nonprofit and technology clients. Mark currently serves as a Chief Financial Officer and consulting CFO (seven years) providing in-house and outsourced CFO and transactional services to the middle market.

      Larry Suarez

      Larry is the CTO for Restech and holds a B.S. in Computer Science. He is a software architect specializing in remote patient monitoring, medical sensors, and clinical trial software. Larry holds a patent on massively distributed computing and has worked for a number of major software startup companies including Sybase, Oracle, and Teradata.  Larry was also the co-founder of a startup to deliver advanced clinical pathways to patients using mobile devices and medical sensors. Larry is truly a pioneer and now a veteran in the deployment.

      Jeff Schipper

      Jeff has a breadth of experience with over 25 years in engineering and executive positions within major fortune 100 healthcare companies. He also has proven success in startup medical technology companies. Jeff provides leadership in securing and managing Restech’s patent portfolio. He also built Restech’s compliance platform that established regulatory acceptance in 25+ countries worldwide. Jeff’s scientific support and in-depth understanding of the device industry set the foundation for current and future commercial innovations at Restech.

      Leo Roucher

      With nearly 30 years of working with physician thought leaders developing novel and emerging technologies, Leo has played a key role in the development and evolution of balloon angioplasty and stent technologies that revolutionized the therapy of cardiac disease. His experience was instrumental in the development of the patented platform technology which drives the Restech sensor. Leo provides a vision and passion for effecting change in the diagnosis and management of atypical reflux.

      Deb Krahel

      With over 20 years of executive experience in both the private and public sector, Debra brings a broad understanding of healthcare delivery system. With experience managing products aimed at wide scale disease and population management for 20 million subscribers, Debra has extensive experience in effectively and efficiently developing models of delivery that address specific health issues. Debra has also been involved in the legislative process and served as the elected President of the Independent Physician Association of California. Debra is dedicated to bringing tools to the healthcare market that improve and support the clinical process.